Oireachtas Health Committee seek age restrictions on e-cigarettes and ban on flavourings

Regulations
Jul.19.2022
The committee asked the Minister for Health to look at other countries where ages for vaping and smoking are 21.

A BAN ON flavoured e-cigarettes, e-cigarette ads on social media and bright packaging are just some of the restrictions recommended in a report on pre-legislative scrutiny on a  public health bill published on the weekend.

Oireachtas Health Committee seek age restrictions on e-cigarettes and ban on flavourings

 

The Oireachtas joint committee on health compiled suggestions for the Public Health (Tobacco and Nicotine Inhaling Products) Bill 2019 after meeting with health specialists and representatives of the vaping industry.

 

A key recommendation was that the bill should regulate the flavouring of e-cigarettes and that all flavours except for tobacco, should be strictly prohibited so as not to entice minors.

 

Speaking to the committee, the Irish Heart Foundation called e-cigarette flavours marketing tools “that are almost exclusively directed at young people because if young people are not addicted, there is no business model.”

 

The committee has stated that the Minister for Health should review international studies to consider increasing the age for buying tobacco and nicotine-inhaling products  to 21.

 

Also giving evidence to the committee, the Royal College of Physicians in Ireland (RCPI) stated that teenagers are more likely to use flavoured nicotine products than other age groups.

 

However, the RCPI also told the committee that a recent study examining the effects of a similar ban in Finland did not report a significant change in e-cigarette use post introduction.

 

Many of the proposals made by the committee indicate a desire to treat e-cigarettes more like traditional cigarettes, such as a move to introduce plain packaging rather than what the Irish Cancer Society has called “cartoon-type packaging”.

 

According to a 2019 European School Survey Project on Alcohol and Other Drugs (ESPAD) vaping among young people is now more common than smoking and more young people aged 12-17 years have tried vaping (22%) compared to adults (14%).

 

The survey also found that in 15 and 16 year olds, almost four in 10 students (39%) had tried e-cigarettes and almost one in 5 (18%) were current users.

 

However, the sale of e-cigarettes to under-18s is still not against the law despite the fact that public health officials as well as representatives of the vaping industry have been advocating for it for years.

 

In response to the report’s publication Vape Business Ireland stated that the complexity of the suggestions would only delay the bill and the under-18s ban.

 

It also claimed that the committee referred to “outdated evidence, as well as research which falls short of international standards”.

 

Another measure in the report would ban the sale of e-cigarettes from temporary units such as kiosks, stalls or marquees at festivals and introduce a license for approved sellers.

 

The report also urges that the bill  contain measures to ban all forms of e-cigarette advertising on billboards, online on all social media platforms, and influencer marketing methods.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
EU Trade Department Faces Scrutiny Over Contacts With Tobacco Industry
EU Trade Department Faces Scrutiny Over Contacts With Tobacco Industry
European Ombudswoman Teresa Anjinho has opened an inquiry into how the European Commission’s Directorate-General for Trade handles interactions with the tobacco industry. The case follows a complaint from a civil society organisation that alleges regular, unnecessary and non-transparent contacts between DG TRADE and tobacco industry representatives, raising questions over compliance with the EU’s obligations under the WHO Framework Convention on Tobacco Control. The inquiry remains ongoing, and the Ombudswoman has not reached any finding of maladministration.
Aug.24
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Germany Probes 7.6 Million Illegal Vape Case With Estimated €33.3 Million Tax Loss; Four Chinese Manufacturer Employees Under Investigation, Some Packaging in Enforcement Images Resembles FUMOT Products
Germany Probes 7.6 Million Illegal Vape Case With Estimated €33.3 Million Tax Loss; Four Chinese Manufacturer Employees Under Investigation, Some Packaging in Enforcement Images Resembles FUMOT Products
German prosecutors and customs authorities are conducting a criminal investigation into an alleged cross-border organised vape network. Authorities say that between January 2024 and March 2025, four employees of an unnamed Chinese e-cigarette manufacturer allegedly built a network of sales agents and wholesalers that brought more than 7.6 million nicotine disposable vapes into Germany, causing an estimated €33.3 million in excise-tax losses. The manufacturer has not been named. Some products visible in enforcement images have packaging resembling products from FUMOT’s portfolio. European regulatory records from 2024, FUMOT’s public overseas-sales materials and records involving German vape importer and distribution company Zamu-Pro GmbH also show FUMOT/RandM products and German distribution activity during the period covered by the investigation.
Sep.21
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05